NO20081908L - Selektive Y4-reseptoragonister for terapeutiske intervensjoner - Google Patents

Selektive Y4-reseptoragonister for terapeutiske intervensjoner

Info

Publication number
NO20081908L
NO20081908L NO20081908A NO20081908A NO20081908L NO 20081908 L NO20081908 L NO 20081908L NO 20081908 A NO20081908 A NO 20081908A NO 20081908 A NO20081908 A NO 20081908A NO 20081908 L NO20081908 L NO 20081908L
Authority
NO
Norway
Prior art keywords
selective
receptor agonists
therapeutic interventions
thr30
obesity
Prior art date
Application number
NO20081908A
Other languages
English (en)
Inventor
Thue Schwartz
Paul Brian Little
Lars-Ole Gerlach
Christian Elling
Original Assignee
7Tm Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As
Publication of NO20081908L publication Critical patent/NO20081908L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

Y4-reseptoragonistpeptid utvalgt fta gruppen bestående av: [A1a30]PP2-36, [Thr30]PP2-36, [Asn30]PP2-36, [G1n30]PP2-36, [Glu10]PP2-36, [G1u10, Leu17, Thr30]PP2-36, [Nle17, Nle30]PP2-36, [G1u10, N1e17, N1e30] PP2-36, deres PPI-36 ekvivalenter, og analoger og avledninger derav som beskrevet i foreliggende beskrivelse, er selektive agonister av Y4-reseptoren relativt til Yl- og Y2-reseptorene, og er nyttige i behandlingen, feks. av fedme og overvekt, og tilstander hvori disse er ansett som bidragende faktorer, og i behandlingen av diaré og tarmhyperutskillelse.
NO20081908A 2005-09-21 2008-04-21 Selektive Y4-reseptoragonister for terapeutiske intervensjoner NO20081908L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010314 WO2007038942A1 (en) 2005-09-21 2005-09-21 Y4 selective receptor agonists for therapeutic interventions

Publications (1)

Publication Number Publication Date
NO20081908L true NO20081908L (no) 2008-06-20

Family

ID=35976513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081908A NO20081908L (no) 2005-09-21 2008-04-21 Selektive Y4-reseptoragonister for terapeutiske intervensjoner

Country Status (11)

Country Link
US (1) US8022035B2 (no)
EP (1) EP1934254A1 (no)
JP (1) JP2009508885A (no)
CN (1) CN101268099A (no)
AU (1) AU2005337116A1 (no)
BR (1) BRPI0520563A2 (no)
CA (1) CA2623088A1 (no)
EA (1) EA200800874A1 (no)
IL (1) IL189938A0 (no)
NO (1) NO20081908L (no)
WO (1) WO2007038942A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005224027B2 (en) * 2004-03-17 2011-05-26 7Tm Pharma A/S Y2/Y4 selective receptor agonists for therapeutic interventions
CN100425282C (zh) * 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
EA200800875A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
EA200800874A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CN101970475A (zh) * 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
CA2988500A1 (en) 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
US5516653A (en) 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
EP0932614A1 (en) 1996-09-09 1999-08-04 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
AU757658B2 (en) * 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU2002230843B8 (en) 2000-12-14 2007-05-17 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
US6588708B2 (en) 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
JP2007512365A (ja) 2003-11-25 2007-05-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 選択的神経ペプチドｙ２受容体作動薬
JP5638177B2 (ja) * 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
PL2060266T3 (pl) * 2004-03-17 2012-01-31 7Tm Pharma As Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych
AU2005224027B2 (en) 2004-03-17 2011-05-26 7Tm Pharma A/S Y2/Y4 selective receptor agonists for therapeutic interventions
CN100425282C (zh) 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
EA200800874A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
EA200800875A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment

Also Published As

Publication number Publication date
IL189938A0 (en) 2008-08-07
CN101268099A (zh) 2008-09-17
EP1934254A1 (en) 2008-06-25
JP2009508885A (ja) 2009-03-05
WO2007038942A1 (en) 2007-04-12
US20090118178A1 (en) 2009-05-07
EA200800874A1 (ru) 2008-08-29
AU2005337116A1 (en) 2007-04-12
US8022035B2 (en) 2011-09-20
CA2623088A1 (en) 2007-04-12
BRPI0520563A2 (pt) 2009-05-19

Similar Documents

Publication Publication Date Title
BRPI0520563A2 (pt) agonistas de receptores y4 seletivos para intervenções terapêuticas
DK2049478T3 (da) Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf
DK2084172T3 (da) Nye 1,4-benzothiepin-1,1-dioxidderivater, som er substitueret med benzylrester, fremgangsmåde til deres fremstilling, lægemidler, der indeholder disse forbindelser, og deres anvendelse
NO20084364L (no) Azetidin derivater som G-protein koblet reseptor (GPR119) agonister
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DK1984345T3 (da) Benzoxaziner og beslægtede nitrogenholdige heterobicykliske forbindelser, der kan anvendes som mineralcorticoidreceptormodulerende midler
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
NO20090628L (no) Pyridizinon derivativater
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
DK2076260T3 (da) N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
NO20084850L (no) MGLUR5 modulatorer I
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
DE602007006040D1 (de) Hemmstoffe des progesteron-rezeptors
NO20084458L (no) IL-8-reseptorantagonister
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
DK2036892T3 (da) 1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2125788T3 (da) Heterocykliske forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application